NCT04971226
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04971226
Title A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS

Facility Status City State Zip Country Details
Rocky Mountain Cancer Centers Denver Colorado 80218 United States Details
Florida Cancer Specialists Fort Myers Florida 33901 United States Details
Florida Cancer Specialists Pan Tallahassee Florida 32308 United States Details
University of Kentucky Lexington Kentucky 40536 United States Details
Uni of Massachusetts Medical Center Worcester Massachusetts 01655 United States Details
Wake Forest University Baptist Medical Center Winston-Salem North Carolina 27157 United States Details
Williamette Cancer Center Eugene Oregon 97401 United States Details
Oregon Health Sciences University Portland Oregon 97239 United States Details
Avera Cancer Sioux Falls South Dakota 57105 United States Details
Chattanooga Onc And Hem Assoc PC Chattanooga Tennessee 37404 United States Details
Texas Oncology-Baylor USO Dallas Texas 75246 United States Details
Texas Oncology Dallas Texas 75246 United States Details
Texas Oncology Dallas Texas 75251 United States Details
Novartis Investigative Site Kingswood New South Wales 2747 Australia Details
Novartis Investigative Site Port Macquarie New South Wales 2444 Australia Details
Novartis Investigative Site Adelaide South Australia 5000 Australia Details
Novartis Investigative Site Southport 4215 Australia Details
Novartis Investigative Site Linz Upper Austria 4010 Austria Details
Novartis Investigative Site Leuven Vlaams Brabant 3000 Belgium Details
Novartis Investigative Site Brussels 1000 Belgium Details
Novartis Investigative Site Varna 9010 Bulgaria Details
Novartis Investigative Site Calgary Alberta T2N 5G2 Canada Details
Novartis Investigative Site Hamilton Ontario L8V 1C3 Canada Details
Novartis Investigative Site Ottawa Ontario K1H 8L6 Canada Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Beijing Beijing Municipality 100010 China Details
Novartis Investigative Site Guangzhou Guangdong 510515 China Details
Novartis Investigative Site Shenzhen Guangdong 518037 China Details
Novartis Investigative Site Zhengzhou Henan 450008 China Details
Novartis Investigative Site Wuhan Hubei 430022 China Details
Novartis Investigative Site Nanjing Jiangsu 210000 China Details
Novartis Investigative Site Suzhou Jiangsu 215004 China Details
Novartis Investigative Site Xian Shanxi 710068 China Details
Novartis Investigative Site Chengdu Sichuan 610041 China Details
Novartis Investigative Site Hangzhou Zhejiang 310003 China Details
Novartis Investigative Site Wenzhou Zhejiang 325000 China Details
Novartis Investigative Site Beijing 100044 China Details
Novartis Investigative Site Lanzhou 730000 China Details
Novartis Investigative Site Tianjin 300020 China Details
Novartis Investigative Site Ostrava Poruba 708 52 Czechia Details
Novartis Investigative Site Brno 625 00 Czechia Details
Novartis Investigative Site Hradec Králové 500 05 Czechia Details
Novartis Investigative Site Aarhus N 8200 Denmark Details
Novartis Investigative Site Copenhagen DK-2100 Denmark Details
Novartis Investigative Site Helsinki FIN 00290 Finland Details
Novartis Investigative Site Bordeaux 33076 France Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Nantes 44093 France Details
Novartis Investigative Site Paris 75475 France Details
Novartis Investigative Site Mannheim Baden-Wurttemberg 68305 Germany Details
Novartis Investigative Site Frankfurt am Main Hesse 60590 Germany Details
Novartis Investigative Site Jena Thuringia 07740 Germany Details
Novartis Investigative Site Aachen 52074 Germany Details
Novartis Investigative Site Berlin 13353 Germany Details
Novartis Investigative Site Lübeck 23538 Germany Details
Novartis Investigative Site Debrecen Hajdu Bihar Megye 4032 Hungary Details
Novartis Investigative Site Kaposvár 7400 Hungary Details
Novartis Investigative Site Kecskemét 6001 Hungary Details
Novartis Investigative Site Delhi 110085 India Details
Novartis Investigative Site Petah Tikva 4941492 Israel Details
Novartis Investigative Site Ramat Gan 5265601 Israel Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Bologna BO 40138 Italy Details
Novartis Investigative Site Milan MI 20122 Italy Details
Novartis Investigative Site Reggio Emilia RE 42123 Italy Details
Novartis Investigative Site Roma RM 00161 Italy Details
Novartis Investigative Site Verona VR 37134 Italy Details
Novartis Investigative Site Nagoya Aichi-ken 453-8511 Japan Details
Novartis Investigative Site Toyoake Aichi-ken 470 1192 Japan Details
Novartis Investigative Site Fukuoka Fukuoka 812-8582 Japan Details
Novartis Investigative Site Fukushima Fukushima 960 1295 Japan Details
Novartis Investigative Site Sapporo Hokkaido 060 8648 Japan Details
Novartis Investigative Site Kobe Hyōgo 650-0047 Japan Details
Novartis Investigative Site Kurashiki Okayama-ken 710-8602 Japan Details
Novartis Investigative Site Sakai Osaka 590-0197 Japan Details
Novartis Investigative Site Suita Osaka 565 0871 Japan Details
Novartis Investigative Site Shimotsuke Tochigi 329-0498 Japan Details
Novartis Investigative Site Chūō Yamanashi 409-3898 Japan Details
Novartis Investigative Site Akita 010-8543 Japan Details
Novartis Investigative Site Osaka 545-8586 Japan Details
Novartis Investigative Site Yamagata 990 9585 Japan Details
Novartis Investigative Site Kuantan Pahang 25100 Malaysia Details
Novartis Investigative Site George Town Pulau Pinang 10450 Malaysia Details
Novartis Investigative Site Subang Jaya Selangor 47500 Malaysia Details
Novartis Investigative Site Kuala Selangor 68000 Malaysia Details
Novartis Investigative Site Amsterdam North Holland 1081 HV Netherlands Details
Novartis Investigative Site Bergen NO-5021 Norway Details
Novartis Investigative Site Oslo 0372 Norway Details
Novartis Investigative Site Porto 4200-072 Portugal Details
Novartis Investigative Site Vila Nova de Gaia 4434 502 Portugal Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Singapore 169608 Singapore Details
Novartis Investigative Site Košice 041 90 Slovakia Details
Novartis Investigative Site Uijeongbu-si Gyeonggi-do 11759 South Korea Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Seoul 06351 South Korea Details
Novartis Investigative Site Seoul 06591 South Korea Details
Novartis Investigative Site Granada Andalusia 18014 Spain Details
Novartis Investigative Site El Palmar Murcia 30120 Spain Details
Novartis Investigative Site Pamplona Navarre 31008 Spain Details
Novartis Investigative Site Barcelona 08036 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
Novartis Investigative Site Gothenburg 413 45 Sweden Details
Novartis Investigative Site Lund 221 85 Sweden Details
Novartis Investigative Site Stockholm 141 86 Sweden Details
Novartis Investigative Site Bellinzona 6850 Switzerland Details
Novartis Investigative Site Taichung 40447 Taiwan Details
Novartis Investigative Site London W12 0HS United Kingdom Details
Novartis Investigative Site Nottingham NG5 1PB United Kingdom Details
Novartis Investigative Site Oxford OX3 7LE United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field